It's been another tough week for ASX healthcare but Morgans' Scott Power said there's been bright spots with Racura soaring on trial news.

BCUHB patient waited three times longer than he should have for prostate cancer treatment. Delays likely advanced his condition, ombudsman finds.

Watchdog finds failings in prostate cancer treatment in North Wales going back almost a decade.

SYDNEY, March 17, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...

HIGHLIGHTS Oral presentation on key results from the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT) was delivered by Prof Louise Emmett (St Vincent's Hospital Sydney) at the European ...

When MRI offered no clear answer in suspected prostate cancer, the use of prostate-specific membrane antigen (PSMA)-PET/CT showed promise for reducing the number of biopsies without compromising the ...

Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate cancer care. The first application is initial s ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research. The findings are ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation ...

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation by Dr. Renu Eapen discussing the optimal management of de-novo ...